98%
921
2 minutes
20
Delirium represents a common terminal pathway of heterogeneous neurological conditions characterized by disturbances in consciousness and attention. Contemporary theories highlight the acute impairment of synaptic function and network connectivity, driven by neuroinflammation, oxidative stress, and neurotransmitter imbalances. However, established biomarkers are still missing. Innovative diagnostic techniques, such as single-molecule array analysis, enable the detection of biomarkers in blood at picomolar concentrations. This approach paves the way for deeper insights into delirium and potentially therapeutic targets for tailored medical treatments. In a retrospective 3-year study, we investigated seven biomarkers indicative of neuroaxonal damage [neurofilament light chain (NFL), ubiquitin carboxyl-terminal hydrolase (UCHL-1), and tau protein], microglial activation [glial fibrillary acidic protein (GFAP) and soluble triggering receptor expressed on myeloid cells 2 (sTREM2)], and synaptic dysfunction [synaptosomal-associated protein 25 (SNAP-25) and neuronal pentraxin 2 (NPTX2)]. The analysis of 71 patients with delirium, Alzheimer's disease (AD), and non-AD controls revealed that serum NFL levels are higher in delirium cases compared to both AD and non-AD. This suggests that elevated NFL levels in delirium are not exclusively the result of dementia-related damage. Serum tau levels were also elevated in delirium cases compared to controls. Conversely, cerebrospinal fluid (CSF) SNAP-25 showed higher levels in AD patients compared to controls only. These findings add to the increasing body of evidence suggesting that serum NFL could be a valuable biomarker of neuroaxonal damage in delirium research. Although SNAP-25 and NPTX2 did not exhibit significant differences in delirium, the exploration of synaptic biomarkers remains promising for enhancing our understanding of this condition.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10985356 | PMC |
http://dx.doi.org/10.3389/fneur.2024.1356575 | DOI Listing |
Medicine (Baltimore)
August 2025
Department of Neurology, Xuzhou Central Hospital, Xuzhou, Jiangsu, China.
Neurofilament light chain (NfL) is an important biomarker for neuronal damage, widely used in the study of neurodegenerative diseases. The weight-adjusted-waist index (WWI), as a measure of abdominal obesity, is closely related to metabolic diseases. However, the association between WWI and NfL has not been systematically investigated.
View Article and Find Full Text PDFJ Neuroimmunol
August 2025
Department of Neurology, Gifu University Graduate School of Medicine, Gifu, Japan; Center for One Medicine Innovative Translational Research (COMIT), Gifu University, Gifu, Japan.
This study investigated whether serum neurofilament light chain (NFL) levels could predict the prognosis of patients with Glial Fibrillary Acidic Protein Autoimmunity (GFAP-A). The study included 54 patients diagnosed with GFAP-A at Gifu University Graduate School of Medicine between June 2019 and October 2023. Patients with other neurological diseases or antineuronal antibodies were excluded.
View Article and Find Full Text PDFJ Neurol Sci
August 2025
Danish Dementia Research Centre, Copenhagen University Hospital - Rigshospitalet, Blegdamsvej 9, DK2100 Copenhagen, Denmark. Electronic address:
Background: Alzheimer's disease (AD) is characterized by cognitive decline, but the individual progression rates vary. One type of blood-based biomarker that has been widely investigated is neurofilament light chain (NfL), as it reflects measures neuronal damage.
Aim: The aim of the current study was to investigate whether NfL could determine the rate of progression in patients with AD.
Clin Chim Acta
August 2025
Faculty of Pharmacy, AIMST University, Bedong, Kedah 08100, Malaysia. Electronic address:
Neurofilament light chain (NfL) is a sensitive marker of neuroaxonal injury with growing clinical relevance in Alzheimer's disease (AD). Across cohorts, blood and CSF NfL concentrations are higher in AD than controls, with reported 1.7-1.
View Article and Find Full Text PDFIntensive Care Med Exp
September 2025
Neurosciences Intensive Care Unit, John Radcliffe Hospital, Oxford, UK.
Delirium is a frequent and serious complication of critical illness, yet its pathophysiological mechanisms remain incompletely understood. Serum biomarkers offer a potential avenue for improved diagnosis, risk stratification, and mechanistic insight. This systematic review synthesises evidence from 28 studies evaluating 54 serum biomarkers in relation to delirium among critically ill adult patients.
View Article and Find Full Text PDF